Focused On-demand Library for H(+)/Cl(-) exchange transporter 7

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
P51798

UPID:
CLCN7_HUMAN

ALTERNATIVE NAMES:
Chloride channel 7 alpha subunit; Chloride channel protein 7

ALTERNATIVE UPACC:
P51798; A6NEJ7; A8K5T9; A8K7X1; B3KPN3; E9PDB9; Q9NYX5

BACKGROUND:
H(+)/Cl(-) exchange transporter 7, identified by its alternative names Chloride channel 7 alpha subunit and Chloride channel protein 7, is pivotal in the exchange of chloride ions for protons. This slowly voltage-gated channel is integral to lysosomal acidification, a process vital for cellular metabolism and ion regulation. The transporter's role as an antiporter is crucial for maintaining the balance of lysosomal pH.

THERAPEUTIC SIGNIFICANCE:
The protein's association with genetic diseases such as Osteopetrosis, autosomal recessive 4, autosomal dominant 2, and a complex syndrome characterized by hypopigmentation and organomegaly, highlights its potential as a target for therapeutic intervention. Exploring the function of H(+)/Cl(-) exchange transporter 7 offers promising avenues for the development of innovative treatments for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8685 of 8789